Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults.

Trial Profile

Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Malaria vaccine (Primary) ; Agatolimod; Aluminium hydroxide
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Feb 2017 According to NCT the study start date, primary completion date and the completion date are all given as 15 Dec 2006, so have not updated it. Study dates retained as per media release.
    • 08 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top